Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018-Reference-Cited by-同舟云学术

Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018

Published:2019-07 Issue:7 Volume:14 Page:1134-1155
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Remon Jordi,Ahn Myung-Ju,Girard Nicolas,Johnson Melissa,Kim Dong-Wan,Lopes Gilberto,Pillai Rathi N.,Solomon Benjamin,Villacampa Guillermo,Zhou Qing

Funder

BerGenBio

Lilly

EMD Serono

Janssen

Mirati Therapeutics

Genmab

Pfizer

AstraZeneca

Genentech

Roche

Stemcentrix

Novartis

Checkpoint Therapeutics

Array BioPharma

Regeneron

Apexigen

Abbvie

Tarveda

Adaptimmune

Syndax

Neovia

Boehringer Ingelheim

Sanofi

Hengrui Therapeutics, Inc.

Merck

Daiichi-Sankyo

Lycera

G1 Therapeutics

Dynavax

Loxo

Cytomx

BeiGene

Birdie

Corvus

Incyte

Genocea

Gritstone

Amgen

Bristol-Myers Squibb

Kadmon

Clovis

Acerta

OncoMed

Guardant Health

Alpha Biopharma

MedImmune

Hanmi

Jansen

Merus

Merck Sharp and Dohme

Ono Pharmaceutical

Takeda

TP Therapeutics

Xcovery

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference146 articles.

1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Aupérin;J Clin Oncol,2010

2. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

3. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC [abstract];Faivre-Finn;Ann Oncol,2018

4. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP);Peters;Ann Oncol,2019

5. Updated results of a phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III NSCLC;Durm;J Thorac Oncol,2018

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy;Journal of Medicinal Chemistry;2024-08-01

2. Predicting Durable Clinical Benefits of Postoperative Adjuvant Chemotherapy in Non-small Cell Lung Cancer: A Nomogram Based on CT Imaging and Immune Type;Academic Radiology;2024-08

3. Accuracy of machine learning in preoperative identification of genetic mutation status in lung cancer: A systematic review and meta-analysis;Radiotherapy and Oncology;2024-07

4. CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer;Molecular Therapy;2024-07

5. SPP1 promotes brain metastasis of NSCLC by up-regulating PI3K/AKT/mTOR pathway;2023-10-31